A systematic review registered under PROSPERO (CRD42021259519) reaffirmed that among salivary biomarkers for GC, the trio CSTB, TPI1, and DMBT1 emerged with the highest diagnostic accuracy in preclinical validation stages (Zúñiga-Pérez et al., 2024). This evidence concerns the gene DMBT1 and gastric cancer.